HIM
VRTX icon

Hillsdale Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Hillsdale Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,385
Closed -$436K – 660
2023
Q1 		$436K Sell
1,385
-565
-29% -$169K 0.04% 347
2022
Q4 		$563K Buy
1,950
+40
+2% +$12.2K 0.05% 293
2022
Q3 		$552K Sell
1,910
-50
-3% -$14.4K 0.05% 302
2022
Q2 		$553K Sell
1,960
-200
-9% -$53.5K 0.04% 308
2022
Q1 		$564K Buy
2,160
+50
+2% +$11.9K 0.04% 354
2021
Q4 		$463K Buy
2,110
+35
+2% +$6.81K 0.03% 382
2021
Q3 		$377K Hold
2,075
– – 0.03% 403
2021
Q2 		$419K Buy
2,075
+60
+3% +$12.6K 0.03% 396
2021
Q1 		$433K Buy
2,015
+50
+3% +$11K 0.04% 375
2020
Q4 		$464K Hold
1,965
– – 0.04% 363
2020
Q3 		$535K Hold
1,965
– – 0.05% 302
2020
Q2 		$570K Sell
1,965
-475
-19% -$129K 0.05% 296
2020
Q1 		$581K Hold
2,440
– – 0.07% 262
2019
Q4 		$535K Sell
2,440
-260
-10% -$52.6K 0.05% 330
2019
Q3 		$458K Sell
2,700
-100
-4% -$17.7K 0.04% 371
2019
Q2 		$513K Hold
2,800
– – 0.05% 327
2019
Q1 		$515K Buy
2,800
+360
+15% +$66.5K 0.05% 303
2018
Q4 		$405K Sell
2,440
-370
-13% -$64.1K 0.05% 315
2018
Q3 		$542K Hold
2,810
– – 0.07% 162
2018
Q2 		$477K Sell
2,810
-10
-0.4% -$1.55K 0.06% 196
2018
Q1 		$460K Sell
2,820
-100
-3% -$16.3K 0.06% 186
2017
Q4 		$438K Buy
2,920
+100
+4% +$14.8K 0.07% 221
2017
Q3 		$429K Buy
2,820
+420
+18% +$63.2K 0.07% 206
2017
Q2 		$309K Buy
+2,400
New +$289K 0.06% 249

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hillsdale Investment Management's VRTX Position: Q2 2023 in Review

Hillsdale Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2023, closing a stake of 1,385 shares — an estimated $436K sold.

Hillsdale Investment Management first reported a position in VRTX in Q2 2017 and held it in 24 quarters. The position peaked at $581K in Q1 2020. 1,286 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

  • Hillsdale Investment Management reported no remaining Vertex Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Hillsdale Investment Management sold 1,385 Vertex Pharmaceuticals shares in Q2 2023, an estimated $436K.
  • Hillsdale Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2017 and held it in 24 quarters.
  • Hillsdale Investment Management's Vertex Pharmaceuticals position peaked at $581K in Q1 2020.
  • 1,286 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on Hillsdale Investment Management's 13F filing for Q2 2023, filed 11 Aug 2023.